Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the
Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the quarter ended June 30, 2002, including an affirmative disclosure that the report has been reviewed consistent with SAS 71, as well as a Form 10-Q for the quarter ended Sept. 30, 2002. Alliance Pharmaceutical had no such recourse. The company announced Oct. 17 its delisting from the exchange for failure to meet certain requirements. The company¹s stock is now being traded on Nasdaq's over-the-counter bulletin board.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.